Non-small Cell Lung Cancer (NSCLC) Clinical Trials

38 recruiting

Non-small Cell Lung Cancer (NSCLC) Trials at a Glance

51 actively recruiting trials for non-small cell lung cancer (nsclc) are listed on ClinicalTrialsFinder across 6 cities in 46 countries. The largest study group is Phase 2 with 24 trials, with the heaviest enrollment activity in Houston, Fairfax, and San Antonio. Lead sponsors running non-small cell lung cancer (nsclc) studies include Bristol-Myers Squibb, Revolution Medicines, Inc., and Merck Sharp & Dohme LLC.

Browse non-small cell lung cancer (nsclc) trials by phase

Treatments under study

About Non-small Cell Lung Cancer (NSCLC) Clinical Trials

Looking for clinical trials for Non-small Cell Lung Cancer (NSCLC)? There are currently 38 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-small Cell Lung Cancer (NSCLC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-small Cell Lung Cancer (NSCLC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 51 trials

Recruiting
Phase 1Phase 2

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small Cell Lung
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled5 locationsNCT07458347
Recruiting
Phase 1

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc.40 enrolled15 locationsNCT07140016
Recruiting
Phase 3

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb850 enrolled254 locationsNCT07361497
Recruiting
Phase 3

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Non-small Cell Lung Cancer (NSCLC)
AstraZeneca400 enrolled204 locationsNCT07291037
Recruiting
Phase 3

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC520 enrolled156 locationsNCT06305754
Recruiting
Phase 3

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled218 locationsNCT06170788
Recruiting
Phase 3

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC556 enrolled194 locationsNCT06074588
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Pancreatic Adenocarcinoma+2 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)ER+, HER 2- Breast Cancer
IDEAYA Biosciences160 enrolled6 locationsNCT07540572
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

Non-small Cell Lung Cancer (NSCLC)High-grade Serous Ovarian Carcinoma (HGSOC)Uterine Serous Carcinoma (USC)
Bristol-Myers Squibb240 enrolled17 locationsNCT06476808
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Malignancies+1 more
Bristol-Myers Squibb252 enrolled8 locationsNCT07223047
Recruiting
Phase 3

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Non-small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc.180 enrolled29 locationsNCT07154706
Recruiting
Phase 2

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)
Genmab240 enrolled8 locationsNCT07288177
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
Not Applicable

Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases

Brain Metastases From Breast CancerBrain Metastases From Non-small Cell Lung Cancer (NSCLC)Brain Metastases From Melanoma
The Netherlands Cancer Institute100 enrolled1 locationNCT07511933
Recruiting
Phase 1Phase 2

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Advanced Solid TumorsNSCLC+3 more
Revolution Medicines, Inc.370 enrolled5 locationsNCT07397338
Recruiting
Not Applicable

Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients

Non-small Cell Lung Cancer (NSCLC)Stage IV
Swiss Cancer Institute128 enrolled7 locationsNCT06114108
Recruiting
Phase 1

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Ovarian CancerCervical Cancer+4 more
Radiopharm Theranostics, Ltd9 enrolled2 locationsNCT05799274
Recruiting

UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance

Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
AstraZeneca300 enrolled52 locationsNCT06726720